Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Медицинские критерии приемлемости для использования методов контрацепции
Медицинские критерии приемлемости для использования методов контрацепции
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Предотвращение абортов и их осложнений – приоритетная задача в сохранении репродуктивного здоровья женщины. Неоценимую роль в этом играет рациональная контрацепция. Анализу медицинских критериев приемлемости методов контрацепции посвящена данная статья.
Ключевые слова: контрацепция, критерии приемлемости, планирование семьи.
Key words: contraception, eligibility criteria, family planning.
Ключевые слова: контрацепция, критерии приемлемости, планирование семьи.
________________________________________________
Key words: contraception, eligibility criteria, family planning.
Полный текст
Список литературы
1. Прилепская В.Н. Руководство по контрацепции. М., 2006; с. 294.
2. Серов В.Н. Гормональная контрацепция как метод реабилитации после абортов. Гинекология. 2007; 9 (6).
3. Moreau C, Trussell J, Desfreres J, Bajos N. Patterns of Сontraceptive use before and after abortion: results from a nationally representative survey of women undergoing an abortion in France. Contraception. 2010; 82 (4): 337–44; doi: 10.1016/j.contraception.2010.03.011. Epub 2010.
4. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception 2010; 82 (1): 102–12.
5. Paternoster DM, Riboni F. The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. Transplantation Proceedings 2010; 42 (4): 1162–5.
6. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception 2010; 82: 102–12.
7. Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review. Contraception 2009; 80 (4): 381–6. Epub 2009.
8. Tagy AH, Saker ME, Moussa AA, Kolgah A. The effect of low-dose combined oral contraceptive pills versus injectable contraceptive (Depot Provera) on liver function tests of women with compensated bilharzial liver fibrosis. Original research article. Contraception 2001; 64: 173–6.
9. Kapp N, Curtis KM. Hormonal contraceptive use among women with liver tumors: a systematic review. Contraception 2009; 80 (4): 387–90. Epub 2009.
10. Савельева И.С. Медицинские критерии приемлемости использования методов контрацепции ВОЗ: комбинированные оральные контрацептивы. Рос. вестн. акушера-гинеколога. 2010; 3: 64–74.
11. Тарасова М.А., Ярмолинская М.И. Заместительная монотерапия эстрогенами у женщин с гемангиомами печени после пангистерэктомии. Журн. акушерства и женских болезней. 2006; 4: 41–5.
12. Nasr A, Hanan MN. Effect of etonogestrel contraceptive implant (Implanon) on portal blood flow and liver functions. Contraception 2009; 79 (3): 236–9.
13. Contraceptive Choices for Women with Inflammatory Bowel Disease. J Family Planning Reprod Health Care 2003; 29 (3): 127–35.
14. Johnson JV, Lowell J, Badger G, Cushman M. The effects of oral and transdermal hormonal contraception on coagulation factors: a prospective, randomized, cross-over trial. Presented at: Society for Gynecologic Investigation. Toronto, ON, Canada, 2006.
15. Kiriwat O, Petyim S. The effects of transdermal contraception on lipid profiles, carbohydrate metabolism and coagulogram in Thai women. Gynecol Endocrinol 2010; 26 (5): 361–5.
16. Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z et al. Oral and transdermal hormonal contraception in women after kidney transplantation. Transplantation Proceedings 2007; 39 (9): 2759–62.
17. Szlendak-Sauer K. The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function. Ginekologia Polska 2009; 80 (2): 99–102.
2. Серов В.Н. Гормональная контрацепция как метод реабилитации после абортов. Гинекология. 2007; 9 (6).
3. Moreau C, Trussell J, Desfreres J, Bajos N. Patterns of Сontraceptive use before and after abortion: results from a nationally representative survey of women undergoing an abortion in France. Contraception. 2010; 82 (4): 337–44; doi: 10.1016/j.contraception.2010.03.011. Epub 2010.
4. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception 2010; 82 (1): 102–12.
5. Paternoster DM, Riboni F. The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. Transplantation Proceedings 2010; 42 (4): 1162–5.
6. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception 2010; 82: 102–12.
7. Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review. Contraception 2009; 80 (4): 381–6. Epub 2009.
8. Tagy AH, Saker ME, Moussa AA, Kolgah A. The effect of low-dose combined oral contraceptive pills versus injectable contraceptive (Depot Provera) on liver function tests of women with compensated bilharzial liver fibrosis. Original research article. Contraception 2001; 64: 173–6.
9. Kapp N, Curtis KM. Hormonal contraceptive use among women with liver tumors: a systematic review. Contraception 2009; 80 (4): 387–90. Epub 2009.
10. Савельева И.С. Медицинские критерии приемлемости использования методов контрацепции ВОЗ: комбинированные оральные контрацептивы. Рос. вестн. акушера-гинеколога. 2010; 3: 64–74.
11. Тарасова М.А., Ярмолинская М.И. Заместительная монотерапия эстрогенами у женщин с гемангиомами печени после пангистерэктомии. Журн. акушерства и женских болезней. 2006; 4: 41–5.
12. Nasr A, Hanan MN. Effect of etonogestrel contraceptive implant (Implanon) on portal blood flow and liver functions. Contraception 2009; 79 (3): 236–9.
13. Contraceptive Choices for Women with Inflammatory Bowel Disease. J Family Planning Reprod Health Care 2003; 29 (3): 127–35.
14. Johnson JV, Lowell J, Badger G, Cushman M. The effects of oral and transdermal hormonal contraception on coagulation factors: a prospective, randomized, cross-over trial. Presented at: Society for Gynecologic Investigation. Toronto, ON, Canada, 2006.
15. Kiriwat O, Petyim S. The effects of transdermal contraception on lipid profiles, carbohydrate metabolism and coagulogram in Thai women. Gynecol Endocrinol 2010; 26 (5): 361–5.
16. Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z et al. Oral and transdermal hormonal contraception in women after kidney transplantation. Transplantation Proceedings 2007; 39 (9): 2759–62.
17. Szlendak-Sauer K. The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function. Ginekologia Polska 2009; 80 (2): 99–102.
2. Серов В.Н. Гормональная контрацепция как метод реабилитации после абортов. Гинекология. 2007; 9 (6).
3. Moreau C, Trussell J, Desfreres J, Bajos N. Patterns of Сontraceptive use before and after abortion: results from a nationally representative survey of women undergoing an abortion in France. Contraception. 2010; 82 (4): 337–44; doi: 10.1016/j.contraception.2010.03.011. Epub 2010.
4. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception 2010; 82 (1): 102–12.
5. Paternoster DM, Riboni F. The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. Transplantation Proceedings 2010; 42 (4): 1162–5.
6. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception 2010; 82: 102–12.
7. Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review. Contraception 2009; 80 (4): 381–6. Epub 2009.
8. Tagy AH, Saker ME, Moussa AA, Kolgah A. The effect of low-dose combined oral contraceptive pills versus injectable contraceptive (Depot Provera) on liver function tests of women with compensated bilharzial liver fibrosis. Original research article. Contraception 2001; 64: 173–6.
9. Kapp N, Curtis KM. Hormonal contraceptive use among women with liver tumors: a systematic review. Contraception 2009; 80 (4): 387–90. Epub 2009.
10. Савельева И.С. Медицинские критерии приемлемости использования методов контрацепции ВОЗ: комбинированные оральные контрацептивы. Рос. вестн. акушера-гинеколога. 2010; 3: 64–74.
11. Тарасова М.А., Ярмолинская М.И. Заместительная монотерапия эстрогенами у женщин с гемангиомами печени после пангистерэктомии. Журн. акушерства и женских болезней. 2006; 4: 41–5.
12. Nasr A, Hanan MN. Effect of etonogestrel contraceptive implant (Implanon) on portal blood flow and liver functions. Contraception 2009; 79 (3): 236–9.
13. Contraceptive Choices for Women with Inflammatory Bowel Disease. J Family Planning Reprod Health Care 2003; 29 (3): 127–35.
14. Johnson JV, Lowell J, Badger G, Cushman M. The effects of oral and transdermal hormonal contraception on coagulation factors: a prospective, randomized, cross-over trial. Presented at: Society for Gynecologic Investigation. Toronto, ON, Canada, 2006.
15. Kiriwat O, Petyim S. The effects of transdermal contraception on lipid profiles, carbohydrate metabolism and coagulogram in Thai women. Gynecol Endocrinol 2010; 26 (5): 361–5.
16. Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z et al. Oral and transdermal hormonal contraception in women after kidney transplantation. Transplantation Proceedings 2007; 39 (9): 2759–62.
17. Szlendak-Sauer K. The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function. Ginekologia Polska 2009; 80 (2): 99–102.
________________________________________________
2. Серов В.Н. Гормональная контрацепция как метод реабилитации после абортов. Гинекология. 2007; 9 (6).
3. Moreau C, Trussell J, Desfreres J, Bajos N. Patterns of Сontraceptive use before and after abortion: results from a nationally representative survey of women undergoing an abortion in France. Contraception. 2010; 82 (4): 337–44; doi: 10.1016/j.contraception.2010.03.011. Epub 2010.
4. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception 2010; 82 (1): 102–12.
5. Paternoster DM, Riboni F. The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. Transplantation Proceedings 2010; 42 (4): 1162–5.
6. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception 2010; 82: 102–12.
7. Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review. Contraception 2009; 80 (4): 381–6. Epub 2009.
8. Tagy AH, Saker ME, Moussa AA, Kolgah A. The effect of low-dose combined oral contraceptive pills versus injectable contraceptive (Depot Provera) on liver function tests of women with compensated bilharzial liver fibrosis. Original research article. Contraception 2001; 64: 173–6.
9. Kapp N, Curtis KM. Hormonal contraceptive use among women with liver tumors: a systematic review. Contraception 2009; 80 (4): 387–90. Epub 2009.
10. Савельева И.С. Медицинские критерии приемлемости использования методов контрацепции ВОЗ: комбинированные оральные контрацептивы. Рос. вестн. акушера-гинеколога. 2010; 3: 64–74.
11. Тарасова М.А., Ярмолинская М.И. Заместительная монотерапия эстрогенами у женщин с гемангиомами печени после пангистерэктомии. Журн. акушерства и женских болезней. 2006; 4: 41–5.
12. Nasr A, Hanan MN. Effect of etonogestrel contraceptive implant (Implanon) on portal blood flow and liver functions. Contraception 2009; 79 (3): 236–9.
13. Contraceptive Choices for Women with Inflammatory Bowel Disease. J Family Planning Reprod Health Care 2003; 29 (3): 127–35.
14. Johnson JV, Lowell J, Badger G, Cushman M. The effects of oral and transdermal hormonal contraception on coagulation factors: a prospective, randomized, cross-over trial. Presented at: Society for Gynecologic Investigation. Toronto, ON, Canada, 2006.
15. Kiriwat O, Petyim S. The effects of transdermal contraception on lipid profiles, carbohydrate metabolism and coagulogram in Thai women. Gynecol Endocrinol 2010; 26 (5): 361–5.
16. Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z et al. Oral and transdermal hormonal contraception in women after kidney transplantation. Transplantation Proceedings 2007; 39 (9): 2759–62.
17. Szlendak-Sauer K. The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function. Ginekologia Polska 2009; 80 (2): 99–102.
Авторы
В.Н.Прилепская, Е.А.Межевитинова, Е.Л.Шешко
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.